Seminars in Nuclear Medicine
Volume 39, Issue 2 , Pages 146-153 , March 2009

Radioimmunotherapy of Infectious Diseases

  • Ekaterina Dadachova, PhD

      Affiliations

    • Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY
    • Department of Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY
    • Corresponding Author InformationAddress reprint requests to Ekaterina Dadachova, PhD, Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, 1695A Eastchester Road, Bronx, NY 10461
    • ,
  • Arturo Casadevall, MD, PhD

      Affiliations

    • Department of Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY
    • Department of Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY

References 

  1. Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2:695–703
  2. Dadachova E, Nakouzi A, Bryan R, et al. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A. 2003;100:10942–10947
  3. Dadachova E, Howell RW, Bryan RA, et al. Susceptibility of human pathogens Cryptococcus neoformans and Histoplasma capsulatum to gamma radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med. 2004;45:313–320
  4. Martinez LR, Bryan RA, Apostolidis C, et al. Antibody-guided alpha-radiation effectively damages fungal biofilms. Antimicrob Agents Chemother. 2006;50:2132–2136
  5. Dadachova E, Burns T, Bryan RA, et al. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother. 2004;48:1624–1629
  6. Dadachova E, Patel MC, Toussi S, et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med. 2006;3:e427
  7. Dadachova E, Casadevall A. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Expert Opinion Drug Deliv. 2005;2:1075–1084
  8. van Eerd JE, Oyen WJ, Harris TD, et al. Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes. J Nucl Med. 2005;46:786–793
  9. van Eerd JE, Rennen HJ, Oyen WJ, et al. Scintigraphic detection of pulmonary aspergillosis in rabbits with a radiolabeled leukotriene b4 antagonist. J Nucl Med. 2004;45:1747–1753
  10. Rusckowski M, Gupta S, Liu G, et al. Investigations of a 99mTc-labeled bacteriophage as a potential infection-specific imaging agent. J Nucl Med. 2004;45:1201–1208
  11. Siaens R, Eijsink VG, Dierckx R, et al. 123I-Labeled chitinase as specific radioligand for in vivo detection of fungal infections in mice. J Nucl Med. 2004;45:1209–1216
  12. Lupetti A, Welling MM, Mazzi U, et al. Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections. Eur J Nucl Med Mol Imaging. 2002;29:674–679
  13. Lupetti A, Welling MM, Pauwels EK, et al. Detection of fungal infections using radiolabeled antifungal agents. Curr Drug Targets. 2005;6:945–954
  14. Line BR, Breyer RJ, McElvany KD, et al. Evaluation of human anti-mouse antibody response in normal volunteers following repeated injections of fanolesomab (NeutroSpec), a murine anti-CD15 IgM monoclonal antibody for imaging infection. Nucl Med Commun. 2004;25:807–811
  15. Love C, Tronco GG, Palestro CJ. Imaging of infection and inflammation with 99mTc-Fanolesomab. Q J Nucl Med Mol Imaging. 2006;50:113–120
  16. Spitzer ED, Spitzer SG, Freundlich LF, et al. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet. 1993;341:595–596
  17. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis. 1994;19:1029–1033
  18. Larsen RA, Pappas PG, Perfect J, et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother. 2005;49:952–958
  19. Retallack DM, Woods JP. Molecular epidemiology, pathogenesis, and genetics of the dimorphic fungus Histoplasma capsulatum. Microbes Infect. 1999;1:817–825
  20. Nosanchuk JD, Steenbergen JN, Shi L, et al. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest. 2003;112:1164–1175
  21. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–394
  22. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989;321:1621–1625
  23. Casadevall A, Goldstein H, Dadachova E. Targeting viruses-harboring host cells with radiolabeled antibodies. Expert Opinion Biol Ther. 2007;7:595–597
  24. Dadachova E, Bryan RA, Frenkel A, et al. Evaluation of acute hematological and long-term pulmonary toxicity of radioimmunotherapy of Cryptococcus neoformans infection in murine models. Antimicrob Agents Chemother. 2004;48:1004–1006
  25. Behr TM, Behe M, Stabin MG, et al. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: Therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res. 1999;59:2635–2643
  26. Sharkey RM, Blumenthal RD, Behr TM, et al. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer. 1997;72:477–485
  27. Koenig TR, Munden RF, Erasmus JJ, et al. Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol. 2002;178:1383–1388
  28. Milenic D, Garmestani K, Dadachova E, et al. Radioimmunotherapy of human colon carcinoma xenografts using a (213)Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm. 2004;19:135–147
  29. Macklis RM. How and why does radioimmunotherapy works?. Int J Radiat Oncol Biol Phys. 2004;59:1269–1271
  30. Bryan RA, Huang X, Morgenstern A, et al. Radio-fungicidal effects of external gamma radiation and antibody-targeted beta and alpha radiation on Cryptococcus neoformans. Antimicrob Agents Chemother. 2008;52:2232–2235
  31. Deere D, Shen J, Vesey G, et al. Flow cytometry and cell sorting for yeast viability assessment and cell selection. Yeast. 1998;14:147–160
  32. Benincasa M, Scocchi M, Pacor S, et al. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J Antimicrob Chemother. 2006;58:950–959
  33. Bryan RA, Zaragoza O, Zhang T, et al. Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell. 2005;4:465–475
  34. Madeo F, Herker E, Wissing S, et al. Apoptosis in yeast. Curr Opin Microbiol. 2004;7:655–660
  35. Dadachova E, Bryan RA, Apostolidis C, et al. Interaction of radiolabeled antibodies with fungal cells and components of immune system in vitro and during radioimmunotherapy of experimental fungal infection. J Infect Dis. 2006;193:1427–1436
  36. Dadachova E, Nosanchuk JD, Shi L, et al. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc Natl Acad Sci U S A. 2004;101:14865–14870

 Supported by the National Institute of Allergy and Infectious Disease (NIAID) grant AI60507 (to E.D.) and NIAID grants AI033142 and AI033774 (to A.C.).

PII: S0001-2998(08)00124-4

doi: 10.1053/j.semnuclmed.2008.10.007

Seminars in Nuclear Medicine
Volume 39, Issue 2 , Pages 146-153 , March 2009

Article Tools

* Image Usage & Resolution